Fig. 5.

NAMPT inhibits lipid accumulation by targeting Sirt1/SREBP1 signaling. The WT and FK866-treated mice were fed with HFD for 12 weeks and the livers were isolated from the mice and the protein levels were determined by western blot analysis or the HepG2 cells were treated with different conditions. a Western blot image (left) and quantitative analysis (right) of the Sirt1 protein expression in liver. b Western blot images (left) and quantitative analysis (right) of the protein expressions of AMPKα and phosphorylated AMPKα at threonine 172 (p-AMPKα) in liver. c Western blot images (left) and quantitative analysis (right) of total AKT and phosphorylated AKT pathway in HepG2 cells with FK866 (20 nM) under insulin stimulation at different times. d Western blots images of ACC protein expression and phosphorylation in HepG2 cells treated by FK866 (20 nM) combined with Sirt1 activator (Resveratrol, 50 μM). e-h Western blot images (e-f) and quantitative analysis of FASN (g) and ACC (h) expressions in HepG2 cells treated by oleic acid (OA, 0.5 mM) combined with FK866 (20 nM) or NMN (100 μM) or Resveratrol (50 μM) or EX527 (10 μM). All results were analyzed based on three independent experiments. The data represent the mean ± SEM. *P < 0.05 and **P < 0.01 versus the control; ^# P < 0.05 and ^{# #} P < 0.01 versus OA